Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500689-87-00

Acronym

MK-7075-006

Enrollment

Registered

2022-06-28

Start date

2021-11-05

Completion date

Unknown

Last updated

2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PIK3CA-related overgrowth spectrum (PROS) and Proteus Syndrome (PS)

Brief summary

Number of participants experiencing a Serious Adverse Event (SAE), Number of participants discontinuing study treatment due to an Adverse Event (AE)

Interventions

DRUGMK-7075

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants experiencing a Serious Adverse Event (SAE), Number of participants discontinuing study treatment due to an Adverse Event (AE)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026